Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses.
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Viral
/ blood
Australia
Bites and Stings
Cell Surface Display Techniques
Chiroptera
/ virology
Cross Reactions
/ immunology
Epitopes
/ immunology
HEK293 Cells
Horses
Humans
Lyssavirus
/ classification
Neutralization Tests
Phylogeny
Post-Exposure Prophylaxis
Rabies
/ prevention & control
Rabies Vaccines
/ immunology
Rabies virus
/ immunology
Rhabdoviridae Infections
/ immunology
Vesiculovirus
/ genetics
ABLV
RABV
bat
glycoprotein
lyssaviruses
monoclonal antibodies
neutralization
phage display
rabies
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
01
02
2021
revised:
25
02
2021
accepted:
26
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
13
8
2021
Statut:
epublish
Résumé
Australian bat lyssavirus (ABLV) is a rhabdovirus that circulates in four species of pteropid bats (ABLVp) and the yellow-bellied sheath-tailed bat (ABLVs) in mainland Australia. In the three confirmed human cases of ABLV, rabies illness preceded fatality. As with rabies virus (RABV), post-exposure prophylaxis (PEP) for potential ABLV infections consists of wound cleansing, administration of the rabies vaccine and injection of rabies immunoglobulin (RIG) proximal to the wound. Despite the efficacy of PEP, the inaccessibility of human RIG (HRIG) in the developing world and the high immunogenicity of equine RIG (ERIG) has led to consideration of human monoclonal antibodies (hmAbs) as a passive immunization option that offers enhanced safety and specificity. Using a recombinant vesicular stomatitis virus (rVSV) expressing the glycoprotein (G) protein of ABLVs and phage display, we identified two hmAbs, A6 and F11, which completely neutralize ABLVs/ABLVp, and RABV at concentrations ranging from 0.39 and 6.25 µg/mL and 0.19 and 0.39 µg/mL respectively. A6 and F11 recognize overlapping epitopes in the lyssavirus G protein, effectively neutralizing phylogroup 1 lyssaviruses, while having little effect on phylogroup 2 and non-grouped diverse lyssaviruses. These results suggest that A6 and F11 could be effective therapeutic and diagnostic tools for phylogroup 1 lyssavirus infections.
Identifiants
pubmed: 33804519
pii: v13030391
doi: 10.3390/v13030391
pmc: PMC8001737
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Epitopes
0
Rabies Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Références
J Infect Dis. 2008 Mar 15;197(6):846-53
pubmed: 18271743
J Virol. 2001 Apr;75(7):3268-76
pubmed: 11238853
Case Rep Dermatol. 2019 Feb 14;11(1):40-47
pubmed: 31043938
Bull World Health Organ. 1989;67(6):731-6
pubmed: 2633888
J Virol. 2006 Jan;80(2):891-9
pubmed: 16378991
Annu Rev Med. 2007;58:359-68
pubmed: 16886905
Med J Aust. 2000 Jun 19;172(12):597-9
pubmed: 10914106
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Neuropathol Appl Neurobiol. 1998 Aug;24(4):331-5
pubmed: 9775399
Vet Microbiol. 2014 Oct 10;173(3-4):224-31
pubmed: 25195190
PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133
pubmed: 29261658
J Clin Microbiol. 2008 Apr;46(4):1451-61
pubmed: 18305130
Zoonoses Public Health. 2018 Sep;65(6):742-748
pubmed: 29785730
Virus Res. 2002 Oct;89(1):1-28
pubmed: 12367747
Genome Med. 2021 Jan 11;13(1):5
pubmed: 33430949
PLoS Negl Trop Dis. 2009 Nov 03;3(11):e542
pubmed: 19888334
Clin Infect Dis. 2020 Jun 17;:
pubmed: 32556113
mBio. 2021 Jan 12;12(1):
pubmed: 33436428
J Infect Dis. 2003 Jul 1;188(1):53-6
pubmed: 12825170
Viruses. 2014 Feb 19;6(2):909-26
pubmed: 24556791
Clin Infect Dis. 2018 Jan 18;66(3):387-395
pubmed: 29020321
Virus Res. 2005 Jul;111(1):44-54
pubmed: 15896401
Virology. 1995 Jul 10;210(2):400-8
pubmed: 7542418
J Virol Methods. 2020 Jul;281:113882
pubmed: 32407866
Zoonoses Public Health. 2020 Jun;67(4):435-442
pubmed: 32311218
Pediatrics. 2014 Apr;133(4):e1063-7
pubmed: 24590754
Trop Med Infect Dis. 2017 Sep 20;2(3):
pubmed: 30270905
Virology. 1993 May;194(1):302-13
pubmed: 7683158
Virol J. 2014 Feb 27;11:40
pubmed: 24576301
Virus Res. 2019 Apr 2;263:217-225
pubmed: 30772332
Emerg Infect Dis. 2006 Dec;12(12):1913-8
pubmed: 17326944
Antiviral Res. 2020 Dec;184:104956
pubmed: 33091433
Virus Res. 1998 Apr;54(2):165-87
pubmed: 9696125
Vaccine. 1989 Feb;7(1):10-1
pubmed: 2718603
Arch Virol. 2020 Nov;165(11):2737-2748
pubmed: 32816125
Virology. 1990 Apr;175(2):485-99
pubmed: 2139267
J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626
pubmed: 29860496
Appl Microbiol Biotechnol. 2012 Oct;96(2):357-66
pubmed: 22678022
Med J Aust. 2014 Dec 11;201(11):647-9
pubmed: 25495308
Adv Virus Res. 2019;104:147-183
pubmed: 31439148
Drugs. 2021 Jan;81(1):175-178
pubmed: 33432551
Biochemistry (Mosc). 2018 Jan;83(1):1-12
pubmed: 29534663
Trop Med Infect Dis. 2017;2(3):
pubmed: 28845465
Viruses. 2019 Mar 14;11(3):
pubmed: 30875748
J Virol. 2010 Nov;84(22):11841-8
pubmed: 20826698
Emerg Infect Dis. 1996 Oct-Dec;2(4):327-31
pubmed: 8969249
Vaccine. 2019 Oct 3;37 Suppl 1:A132-A139
pubmed: 30503659
Virology. 2013 Sep;444(1-2):21-30
pubmed: 23849788